Clinical trial · Interventional
Prospective Cohort With Clinic-biologic Database of Patients Treated by Immunotherapy
NCT05223608CI-TRIAL-00106710ImmuCCorecruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
ImmuCCo-1905 is a monocentric interventional study on patients treated by immunotherapy, which consist in establishment of a prospective clinic-biologic database over 5 years, associated with a biobank. This database will allow carrying out works aiming at assessing immunotherapy in real life situation.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Solid Tumor, Adult | Adult Solid Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| ImmuCCo Cohort | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- ImmuCCo Cohort
- description
- Blood sampling at initiation of immunotherapy, at the first tumor assessment, in case of severe toxicity. Urine collection at initiation of immunotherapy.
- interventionNames
- Other: ImmuCCo Cohort
Primary outcomes (1)
- measure
- Number of patients treated by immunotherapy and registered in the database.
- timeFrame
- 5 years
- description
- Number of patients treated by immunotherapy and registered in the database
Secondary outcomes (5)
- measure
- Overall Survival
- timeFrame
- 6 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥ 18 years * Beginning a first immunotherapy by immune checkpoint inhibitor - anti-PD1 (Programmed cell Death protein-1), anti-PDL1 (Programmed cell Death protein-1 ligand), anti-CTLA4 (Cytotoxic T-Lymphocyte associated protein 4), as monotherapy or in combination, in the Centre Oscar Lambret (COL) * In neo-adjuvant, adjuvant, recurrence or metastatic situation * Suffering from solid tumor histologically documented * Signed written informed consent * Patient covered by the French " "Social Security" regime If the patient is already enrolled in clinical trial involving immunotherapy, the agreement of the sponsor of this new trial will be sought before his/her inclusion. Exclusion Criteria: * Pregnant or breastfeeding women * Patient already treated by immunotherapy by immune checkpoint inhibitor * Person under guardianship * Inability to comply with medical follow-up of the trial (geographical, social or psychic reasons)
References
Publications (0)
Data not yet available
No reference posted for this study.